3-methanesulfonylpropionitrile for treating inflammation and/or pain
The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable solvate thereof, wherein the composition is in an oral form of tablets, capsules, or syrups.
2. The pharmaceutical composition of claim 1 , wherein the compound is at least 90% (w/w) pure.
3. The pharmaceutical composition of claim 2 , wherein the compound is at least 95% (w/w) pure.
4. The pharmaceutical composition of claim 1 , wherein the oral form is a tablet.
5. The pharmaceutical composition of claim 1 , wherein the oral form is a capsule.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable solvate thereof, wherein the composition is in a topical form of gels, creams, lotions, or patches.
7. The pharmaceutical composition of claim 6 , wherein the compound is at least 90% (w/w) pure.
8. The pharmaceutical composition of claim 7 , wherein the compound is at least 95% (w/w) pure.
9. The pharmaceutical composition according to claim 6 , the compound is in an amount of about 0.5-10% (w/w).
10. The pharmaceutical composition according to claim 6 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethylether, caprylic/capric triglyceride, octisalate, silicone fluid, Squalene, and sunflower oil.
11. The pharmaceutical composition according to claim 6 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethylether.
12. The pharmaceutical composition according to claim 11 , wherein the permeation enhancer is diethylene glycol monoethylether.
13. The pharmaceutical composition according to claim 11 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.